Kincaid's specifically built Pro 2 racing truck features two-wheel drive, 750 horsepower, and 20-inch wheel travel, and is sprayed with Rhino Linings spray-on bedliner formula along the lower ...

(RTTNews) - Sanofi announced that Beyfortus (nirsevimab) will be broadly available for babies born in Ontario, Quebec, Nunavut, Northwest Territories, and the Yukon this fall. The administration ...

Show attendees will experience a Professional Short Course Off-Road Pro 2 vehicle, Ram 2500 Diesel and a customized Jeep Gladiator all using Rhino Linings' spray-on products Kincaid's specifically ...

But, if you’re really trying to cut down your energy bill, have countless clothes that need a quick freshen-up or simply just hate doing laundry, then a clothes refresher spray may offer some ...

Sanofi (NASDAQ:SNY) shares gained on Friday after the French pharma giant exceeded analysts' estimates with its Q3 thanks mainly to earlier-than-anticipated vaccine sales and a 22% YoY rise in ...

Protect yourself and your family from annoying bug bites with one of the best bug sprays on the market. Whether you're on a run or sitting on your patio, it's important to protect your exposed ...

Despite Merck & Co. homing in on approval for its infant respiratory syncytial virus (RSV) antibody clesrovimab, Sanofi—which last year won its own nod for its AstraZeneca-partnered RSV ...

Sanofi expects a low single-digit decline in flu shot sales due to the soft vaccination rate. Sanofi reaffirms that Dupixent will deliver around 13 billion euros in 2024 sales. The company ...

Agomab Ther­a­peu­tics is ben­e­fit­ing from Sanofi’s push to be­come an im­munol­o­gy pow­er­house.

(Reuters) - French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, boosted by an earlier-than-anticipated start of the vaccination season.

Sanofi reported a 25% boost in sales for its vaccines division during the third quarter, helped by earlier-than-anticipated orders of its flu shots as well as rising revenue from Beyfortus, its RSV ...

Leerink Partners analyst David Risinger in a Friday note to investors said Sanofi expects Q4 Beyfortus sales similar to Q3. Sanofi released its third-quarter earnings report on Friday, beating ...